DE69334129D1 - Modulierung der TNF-Rezeptoraktivität - Google Patents

Modulierung der TNF-Rezeptoraktivität

Info

Publication number
DE69334129D1
DE69334129D1 DE69334129T DE69334129T DE69334129D1 DE 69334129 D1 DE69334129 D1 DE 69334129D1 DE 69334129 T DE69334129 T DE 69334129T DE 69334129 T DE69334129 T DE 69334129T DE 69334129 D1 DE69334129 D1 DE 69334129D1
Authority
DE
Germany
Prior art keywords
tnf
modulation
receptor activity
tnf receptor
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334129T
Other languages
English (en)
Other versions
DE69334129T2 (de
Inventor
David Wallach
Cord Brakebusch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69334129D1 publication Critical patent/DE69334129D1/de
Publication of DE69334129T2 publication Critical patent/DE69334129T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69334129T 1992-05-03 1993-04-29 Modulierung der TNF-Rezeptoraktivität Expired - Lifetime DE69334129T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL101769A IL101769A (en) 1992-05-03 1992-05-03 Modulation of TNF receptor action
IL101769 1992-05-03

Publications (2)

Publication Number Publication Date
DE69334129D1 true DE69334129D1 (de) 2007-05-10
DE69334129T2 DE69334129T2 (de) 2007-12-13

Family

ID=11063598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69334129T Expired - Lifetime DE69334129T2 (de) 1992-05-03 1993-04-29 Modulierung der TNF-Rezeptoraktivität

Country Status (8)

Country Link
US (4) US6395267B1 (de)
EP (2) EP1512697A1 (de)
JP (2) JP3712746B2 (de)
AT (1) ATE358178T1 (de)
DE (1) DE69334129T2 (de)
DK (1) DK0568925T3 (de)
ES (1) ES2281070T3 (de)
IL (1) IL101769A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US7235648B1 (en) 1993-03-31 2007-06-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US20030054402A1 (en) 1993-03-31 2003-03-20 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6864060B1 (en) 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
JPH09512704A (ja) * 1994-03-17 1997-12-22 ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン シグナル変換経路を調節するための産物および方法
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
ES2242195T3 (es) * 1995-02-22 2005-11-01 YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. Moduladores de proteinas reguladoras.
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
IL114461A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev TNF modulation
WO1998014565A1 (en) * 1996-10-04 1998-04-09 Immunex Corporation Novel receptor that causes cell death
EP0938548B1 (de) 1996-11-06 2008-08-06 The Regents of the University of California Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6355473B1 (en) 1998-05-06 2002-03-12 Cadus Pharmaceutical Corp. Yeast cells having mutations in stp22 and uses therefor
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7273747B2 (en) 1998-08-27 2007-09-25 Cadus Technologies, Inc. Cell having amplified signal transduction pathway responses and uses therefor
US6251605B1 (en) 1998-10-27 2001-06-26 Cadus Pharmaceutical Corporation Yeast cells having mutations in Cav1 and uses therefor
WO2000031261A2 (en) 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
IL132105A0 (en) * 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
US6504008B1 (en) 1999-02-01 2003-01-07 Cadus Technologies, Inc. Cell based signal generation
US6555325B1 (en) 1999-06-14 2003-04-29 Cadus Technologies, Inc. System for detection of a functional interaction between a compound and a cellular signal transduction component
US7223533B2 (en) 1999-09-10 2007-05-29 Cadus Technologies, Inc. Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
BRPI0909179A2 (pt) 2008-03-13 2015-08-25 Biotest Ag Composição farmacêutica, e, método de tratamento de uma doença autoimune.
CA2718191C (en) 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
JP5746191B2 (ja) * 2009-10-19 2015-07-08 ハナル バイオファーマ カンパニーリミテッドＨａｎＡｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2657252B1 (de) * 2010-12-23 2017-03-08 HanAll Biopharma Co., Ltd. Modifiziertes menschliches tumornekrose-faktor-rezeptor-1-polypeptid oder fragment davon sowie herstellungsverfahren dafür
DE102013223589B4 (de) 2013-11-19 2016-11-17 Hydrogenious Technologies Gmbh Anlage und Verfahren zum Speichern von Energie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action

Also Published As

Publication number Publication date
US7056505B2 (en) 2006-06-06
US7429379B2 (en) 2008-09-30
JPH06233684A (ja) 1994-08-23
IL101769A (en) 2007-02-11
DK0568925T3 (da) 2007-05-29
JP3683263B2 (ja) 2005-08-17
ATE358178T1 (de) 2007-04-15
EP0568925A2 (de) 1993-11-10
JP2004340975A (ja) 2004-12-02
IL101769A0 (en) 1992-12-30
US20090088558A1 (en) 2009-04-02
EP0568925A3 (de) 1995-03-15
US20020142357A1 (en) 2002-10-03
US7728111B2 (en) 2010-06-01
US20060210560A1 (en) 2006-09-21
EP1512697A1 (de) 2005-03-09
US6395267B1 (en) 2002-05-28
DE69334129T2 (de) 2007-12-13
EP0568925B1 (de) 2007-03-28
ES2281070T3 (es) 2007-09-16
JP3712746B2 (ja) 2005-11-02

Similar Documents

Publication Publication Date Title
ATE358178T1 (de) Modulierung der tnf-rezeptoraktivität
ATE228534T1 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
DE69333027D1 (de) Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
DK0964874T3 (da) CAML-bindende lymfocytoverfladereceptor, nukleinsyrer, som koder derfor, og fremgangsmåder til anvendelse deraf
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
NO963818L (no) Forhöyet utskillelse av polypeptider
EA200000311A1 (ru) Новый белок иммунной системы - кау
AU5931586A (en) Fibronectins
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
DE69022559D1 (de) Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
DE69404401D1 (de) Erythropoietin-Analoga mit zusätzlichen Glycosylierungsstellen
DE68927523D1 (de) Modifikation der Domäne der Konstantregion der Antikörpern
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE3686130D1 (de) Geschmackskontrolle von proteinhydrolysaten.
BG109537A (en) FUNCTION MODULATORS OF RECEPTORS OF TNF / NGF RECIPE FAMILY AND OTHER PROTEINS
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
EP1568708A3 (de) Verfahren und medizinische Verwendungen von Nukleinsäuren die für einen TRAF-Inhibitor kodieren
DE69432413D1 (de) Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
DE68923636D1 (de) Halbleiter-Treiber zur Erzeugung von Schalt- und Offset-Signalen.
AU617982B2 (en) Polypeptides of the rhinovirus strain HRV89 and the DNA molecules coding therefor
AU7574394A (en) TNF inhibitors
NO893548L (no) Fremgangsmaate til fremstilling av fluorsubstituerte 4'-demetylepipodofyllotoksinglukosider.
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
DK0606869T3 (da) Promotorsekvens for p55-receptoren for tumornekrosefaktor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition